🔎 Trials Near Me

Hjem › Overvægt › New York › Rochester

Overvægt kliniske forsøg i Rochester, NY

13 studier for Overvægt søger deltagere på steder i og omkring Rochester (inden for ca. 30 miles). Åbn et studie for at se, hvem der kan deltage, og hvordan man kontakter studieteamet.

Officiel studietekst (engelsk)

Rekrutterer til et studie her? Få det vist øverst på siden — $99 i 30 dage →

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

RekruttererFase 2
  • Rochester Clinical Research /ID# 282484, Rochester
Alder 18 til 75 · Alle køn · Opdateret 2. okt. 2026 · NCT07752979

Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes

RekruttererFase 2
  • Rochester Clinical Research, Rochester
Alder 18 og opefter · Alle køn · Opdateret 29. sep. 2026 · NCT07685808

A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity

RekruttererFase 3
  • Rochester Clinical Research, LLC, Rochester
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT07794579

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

RekruttererFase 3
  • Rochester Clinical Research, LLC, Rochester
Alder 18 og opefter · Alle køn · Opdateret 28. sep. 2026 · NCT07595549

Evaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity

RekruttererFase 3
  • Rochester Clinical Research, Rochester
Alder 45 til 99 · Alle køn · Opdateret 22. sep. 2026 · NCT07037433

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

RekruttererFase 3
  • Rochester Clinical Research, LLC, Rochester
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07321886

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

RekruttererFase 3
  • Rochester Clinical Research, LLC, Rochester
Alder 18 og opefter · Alle køn · Opdateret 22. sep. 2026 · NCT07353931

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

RekruttererFase 2
  • Rochester Clinical Research, LLC, Rochester
Alder 18 til 75 · Alle køn · Opdateret 22. sep. 2026 · NCT07589608

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

RekruttererFase 2
  • Rochester Clinical Research, LLC, Rochester
Alder 18 til 75 · Alle køn · Opdateret 8. sep. 2026 · NCT06143956

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

RekruttererFase 3
  • Rochester Clinical Research, Rochester
Alder 18 til 99 · Alle køn · Opdateret 3. sep. 2026 · NCT07684235

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

RekruttererFase 3
  • Kailera Clinical Site, Rochester
Alder 18 og opefter · Alle køn · Opdateret 3. sep. 2026 · NCT07284875

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

RekruttererFase 3
  • Rochester Clinical Research, Rochester
Alder 18 til 99 · Alle køn · Opdateret 27. aug. 2026 · NCT07575399

Impact of Increased Body Mass Index on Adolescent Fixed Orthodontic Treatment. A Prospective Longitudinal Study

RekruttererObservationsstudieFrivillige med god helbredstilstand velkomne
  • Eastman Institute for Oral Health, University of Rochester, Rochester
Alder 12 til 18 · Alle køn · Opdateret 20. okt. 2025 · NCT07217756

Overvægt forsøg i andre byer

Andre studier i Rochester

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.